Benzodiazepines in FAERS: Adverse Events, Dependence, and Safety Signals

The pharmacovigilance profile of controlled substances is a critical input for clinical risk management, pharmacy benefit design, and regulatory compliance. Among central nervous system (CNS) agents, benzodiazepines occupy a complex clinical position. Indicated for short-term treatment of anxiety, panic disorder, seizures, skeletal muscle spasticity, and alcohol withdrawal, they are also widely recognized for their potential for abuse, misuse, addiction, physical dependence, and withdrawal. The class-wide safety concerns prompted the U.S. Food and Drug Administration (FDA) to issue a significant boxed warning update on September 23, 2020, expanding the historical warnings on concomitant opioid use to cover class-wide risks of dependence and withdrawal.

This analysis provides a descriptive read of benzodiazepine safety reports in the FDA Adverse Event Reporting System (FAERS). By analyzing a cohort of 716,126 adverse-event reports, we map the reporting volumes of specific agents, evaluate the distribution of serious and fatal outcomes, trace the reactions behind the 2020 boxed warning update, and assess the role of polypharmacy and litigation in the reporting record.

---

Quick answer

What is the scenario question? If I am a drug-safety or formulary team reviewing the benzodiazepine class, what does the public FAERS record actually show about report volume, the dependence/overdose signal behind the 2020 boxed warning, and which agents dominate?

Direct Answer: An analysis of the public openFDA FAERS database (export dated June 8, 2026) reveals 716,126 individual reports naming a benzodiazepine in any role (suspect, concomitant, or interacting). Within this cohort, 74.5% of reports are flagged as serious (533,581 cases), and 14.7% record a death outcome (105,128 cases), peaking in 2019 with 54,080 annual reports. Alprazolam leads the class in report volume with 202,864 cases, followed by clonazepam (153,672), lorazepam (146,479), and diazepam (115,621). The signal reactions directly align with the FDA's class-wide boxed warnings: sedation/somnolence (51,790 cases), dependence and withdrawal (48,919 cases), cognitive/confusion effects (42,352 cases), overdose/intoxication (35,808 cases), falls/injuries (31,607 cases), and respiratory depression (20,359 cases). Completed suicide (21,064 cases) and drug interactions (19,697 cases) are prominent. Importantly, the cohort is driven by clinical use rather than litigation, as lawyer reports account for only 1.2% of cases (8,659 reports).

---

Who this is for

• Pharmacovigilance Analysts and Drug-Safety Teams: Identifying baseline safety signals, evaluating the real-world impact of label changes, and comparing drug-class safety profiles.
• Formulary Managers and Clinical Pharmacists: Reviewing utilization criteria, assessing prior-authorization controls, and designing safety-monitoring protocols for controlled substances.
• Psychiatrists and Addiction Medicine Specialists: Aligning prescribing habits with FDA warnings and structuring gradual tapering plans for patients with physical dependence.
• Healthcare Quality Directors and Risk Managers: Designing clinical workflows to mitigate risk, such as fall-prevention protocols for elderly patients prescribed sedatives.

---

Methodology, in one paragraph

A report is counted for the benzodiazepine class when the drug's generic or brand name appears as an exact drug-field token in that report—as a suspect, concomitant, or interacting drug—using an exact-token match across the drug_substances, drug_generics, and drug_brands fields of the openFDA FAERS extract (20,328,575 total reports, export dated June 8, 2026). Because a single report can name several benzodiazepines (often in cases of intentional-overdose polypharmacy or transitions between therapies), the per-substance totals — and the per-substance serious and death counts, which attribute each report's flags to every benzodiazepine named in that report — sum to more than the deduplicated class totals of 716,126 reports, 533,581 serious, and 105,128 deaths. Non-benzodiazepine sedative-hypnotics (Z-drugs: zolpidem, zopiclone, eszopiclone) and barbiturates are excluded. A "serious" report is defined by the presence of an FDA seriousness flag. Outcomes are categorized based on the raw FDA database flags (seriousness equals death or outcome equals Fatal). Reactions are coded according to MedDRA Preferred Terms and are case-normalized. The safety reaction families aggregate related Preferred Terms (for example, "dependence and withdrawal" combines drug dependence, drug withdrawal syndrome, withdrawal syndrome, and drug rehabilitation; "sedation" combines somnolence, sedation, and altered state of consciousness; "overdose/intoxication" combines overdose, accidental overdose, intentional overdose, toxicity, and drug toxicity), counting a report once per family if any matching term is present. For general FAERS context, see inside 20 million FAERS reports analysis; for other class safety cuts, see opioid analgesics in FAERS, SSRI/SNRI antidepressants in FAERS, and antiepileptic drugs in FAERS.

---

Detailed Regulatory History: From Scheduling to Boxed Warnings

To understand the safety signals in FAERS, we must examine the regulatory framework governing benzodiazepines. Benzodiazepines were introduced in the 1960s (chlordiazepoxide in 1960, diazepam in 1963) as safer alternatives to barbiturates, which carried a narrow therapeutic index and high risk of fatal overdose. In 1975, the U.S. Drug Enforcement Administration (DEA) placed the entire benzodiazepine class under Schedule IV of the Controlled Substances Act, recognizing their potential for abuse and dependence, albeit lower than Schedule II opioids or stimulants.

Over the next four decades, clinical usage expanded significantly, with benzodiazepines becoming standard treatments for acute anxiety, insomnia, and muscle spasms. However, the accumulation of real-world evidence eventually forced safety changes:

• The 2016 Opioid-Benzodiazepine Warning: In August 2016, the FDA issued its first class-wide boxed warning for benzodiazepines and opioids, highlighting that concomitant use of these classes leads to profound sedation, respiratory depression, coma, and death. Clinicians were directed to limit co-prescribing to patients with no alternative treatment options.
• The September 23, 2020 Boxed Warning Update: While the 2016 warning targeted co-prescribing, the 2020 safety communication expanded the boxed warning to cover the risks of abuse, misuse, addiction, physical dependence, and withdrawal for the drugs when used alone. The FDA noted that physical dependence can develop after only several days of continuous therapeutic use. The agency also warned that abrupt discontinuation or rapid dosage reduction can precipitate severe, life-threatening withdrawal symptoms, including catatonia, cardiovascular instability, and status epilepticus. Clinicians were mandated to implement a gradual, individualized taper when discontinuing therapy.

---

How many benzodiazepine adverse-event reports are in FAERS, and how serious are they?

The openFDA FAERS database contains 716,126 individual reports where a benzodiazepine is listed in any role. This represents one of the largest controlled-substance cohorts in the safety database, reflecting decades of broad prescribing and patient exposure.

The severity distribution within the benzodiazepine cohort is high:

• The Seriousness Flag: Of the 716,126 reports, 74.5% (533,581 cases) carry an FDA seriousness flag. The 74.5% serious rate is in the same band as broadly prescribed cardiometabolic and chronic-use classes — NSAIDs (~68%) and statins (~69%) — but the benzodiazepine cohort stands out on the death measure, which is driven by the overdose and suicide context rather than by therapeutic-dose toxicity.
• The Fatal Outcome Rate: A total of 14.7% (105,128 cases) record a death outcome (either via the raw seriousness flag or the Fatal outcome field).
• The Longitudinal Trend: Annual reporting volumes peaked in 2019 with 54,080 reports, following a steady decade-long climb, before plateauing slightly in the early 2020s.

Framing the 14.7% Death Share

A critical pharmacovigilance distinction must be made regarding the 14.7% death rate: FAERS data does not prove causality, and this figure does not suggest that benzodiazepines carry a 14.7% mortality risk when used as directed.

The elevated death share reflects the clinical and sociological context of the patient population:

1. Polypharmacy and Co-Prescribing: The majority of fatal reports involve multiple CNS depressants. Concomitant use of opioids and benzodiazepines is a major driver of respiratory depression and fatal overdose.
2. Intentional Overdose and Suicide: Benzodiazepines are frequently present in cases of intentional self-harm. Completed suicide is coded as a reaction in 21,064 cases within the cohort.
3. Comorbid Populations: Patients prescribed benzodiazepines often have severe psychiatric or medical comorbidities, placing them at higher baseline risk for mortality.

---

Which benzodiazepines generate the most reports?

The reporting volume is concentrated among a small number of widely prescribed agents:

• Alprazolam (Xanax): Leads the class with 202,864 reports. Alprazolam’s high reporting volume is driven by its high prescribing rates for anxiety and panic disorder, as well as its rapid onset of action, which is clinically associated with a higher risk of rebound anxiety and abuse.
• Clonazepam (Klonopin): Second in volume with 153,672 reports. Primarily prescribed for panic disorder and seizure management, its longer half-life results in a distinct safety profile characterized by prolonged cognitive impairment.
• Lorazepam (Ativan): Contributes 146,479 reports. Lorazepam is widely used in inpatient settings for acute anxiety, status epilepticus, and alcohol withdrawal, linking it to acute safety reports.
• Diazepam (Valium): Represents 115,621 reports. As one of the oldest benzodiazepines, it retains a significant footprint in skeletal muscle spasm and anxiety management.
• Temazepam (Restoril): Contributes 23,630 reports. It is primarily prescribed for the short-term treatment of severe insomnia, which shapes its safety profile around next-day sleepiness, parasomnias, and dependency.
• Clobazam (Onfi): Contributes 23,603 reports. Approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, its safety profile is dominated by pediatric and young adult seizure-related reports.

Procedural and ICU Sedation Exposure

Safety teams must note that for certain agents, the FAERS record is split between outpatient chronic therapy and acute inpatient/procedural use:

• Midazolam (21,260 reports): Midazolam is almost exclusively used for preoperative sedation, ICU sedation, and anesthesia induction. Its safety reports are dominated by acute, clinician-managed events such as respiratory depression, hypoventilation, and prolonged sedation in hospital settings.
• Lorazepam and Diazepam Injection: These formulations are frequently administered intravenously in emergency departments or intensive care units. The safety profiles of these agents include acute cardiovascular and respiratory events associated with IV administration, which differ from the outpatient oral safety profile.

---

What do the signal reactions say about dependence, withdrawal, and overdose?

The clinical signals visible in the FAERS database align with the warnings on FDA-approved labeling. We mapped the MedDRA Preferred Terms (PTs) to identify the specific safety signals driving the cohort.

Table 2: Signal-Reaction Mapping for the Benzodiazepine Cohort

The 2020 FDA Boxed Warning Context

On September 23, 2020, the FDA mandated an update to the class-wide boxed warning for all benzodiazepines. The update was driven by the recognition that physical dependence can occur within days to weeks of initiating therapy, leaving patients at risk for severe withdrawal symptoms if therapy is discontinued abruptly.

The FAERS database contains 48,919 reports flagging dependence or withdrawal. The symptoms of benzodiazepine withdrawal can be severe, including catatonia, delirium tremens, hallucinations, and life-threatening seizures. Payer prior-authorization policies and clinical taper guidelines must account for this risk:

• Gradual Taper Mandates: Payer policies that limit refills or implement sudden quantity limits must be designed to avoid triggering abrupt cessation. Tapering plans must be individualized and can take months to complete safely.
• The Chronic-Use Paradox: While benzodiazepine labels specify that use should be short-term (e.g., 2 to 4 weeks), a significant portion of FAERS reports involve patients on chronic therapy for months or years, where physical dependence is established.

Safety Concerns in Special Populations: Pregnancy and Neonates

A distinct clinical subset within the dependence and withdrawal signal involves neonatal exposure. Benzodiazepines readily cross the placenta. In utero exposure during late pregnancy can result in:

• Neonatal Withdrawal Syndrome: Characterized by irritability, hypertonia, tremors, and feeding difficulties, requiring pharmacotherapy.
• Floppy Infant Syndrome: Characterized by hypotonia, hypothermia, and respiratory depression in the newborn. Safety teams must monitor these reports, which are often coded in FAERS under "neonatal withdrawal syndrome" or "drug withdrawal syndrome neonatal."

---

Clinical Best Practices: Individualized Tapering Protocols

Given the severity of the withdrawal safety signals documented in FAERS, clinical protocols must prioritize structured, gradual dose reductions. The Ashton Manual (devised by Professor C. Heather Ashton) remains the foundational clinical resource for benzodiazepine withdrawal management:

• The Cross-Taper Strategy: For patients on short-acting benzodiazepines with high binding affinity (such as alprazolam or lorazepam), direct tapering is exceptionally difficult due to inter-dose withdrawal symptoms. Clinical guidelines recommend cross-tapering the patient to an equivalent dose of a long-acting agent with active metabolites, primarily diazepam. Diazepam's long elimination half-life (up to 200 hours including its active metabolite desmethyldiazepam) provides a self-tapering buffer, smoothing the plasma concentration curve.
• Taper Velocity: The velocity of the taper must be customized to the individual patient's duration of use, dosage, and psychiatric stability. A standard protocol involves reducing the daily dose by 5% to 10% every 1 to 2 weeks. For long-term users (e.g., >5 years), the taper may extend over 6 to 12 months, with the final steps of the taper (e.g., reducing diazepam from 2 mg to zero) requiring ultra-slow adjustments or liquid formulations to prevent severe rebound anxiety or seizures.
• Payer and PBM Policy Alignment: Pharmacy benefit managers (PBMs) must design utilization controls that support rather than disrupt tapering workflows. Prior authorization approvals for tapering patients should allow for flexible dosing, intermediate strengths, and extended durations, preventing abrupt coverage terminations that could precipitate medical emergencies.

---

How does the benzodiazepine death share compare to other drug classes?

The 14.7% fatal outcome rate in the benzodiazepine cohort is high. To put this in perspective, we compared it to other drug classes previously analyzed by this publication:

• Diuretics: 11.8% fatal outcome rate (763,189 total reports).
• Beta-Blockers: 10.1% fatal outcome rate (889,297 total reports).
• SSRI/SNRI Antidepressants: 9.0% fatal outcome rate (968,183 total reports).
• NSAIDs: 9.0% fatal outcome rate (1,536,590 total reports).
• JAK Inhibitors: 3.3% fatal outcome rate (242,498 total reports).

The comparison demonstrates that benzodiazepines carry a fatal outcome footprint that exceeds other CNS and cardiovascular drug classes. This difference is not due to intrinsic therapeutic toxicity, but rather to the abuse and overdose context.

According to the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) analyzing overdose trends, benzodiazepines were involved in 6,982 overdose deaths (16.8% of the total) across 23 states between January 2019 and June 2020. The National Institute on Drug Abuse (NIDA) reported 10,870 benzodiazepine-involved overdose deaths in 2023 in the United States. In the vast majority of these deaths, the benzodiazepine was co-ingested with an opioid (such as illicit fentanyl or prescription oxycodone), which synergistically amplifies respiratory depression. Indeed, a landmark publication (PMC9198172) examining 118,208 benzodiazepine-involved overdose deaths between 2000 and 2019 in the USA confirmed that co-ingested opioids were present in over 70% of the cases, demonstrating the high risk of polypharmacy in this population.

---

Who reports benzodiazepine events, and is the record litigation-driven?

Spontaneous safety reporting databases can be distorted by litigation. When a drug becomes the subject of a class-action lawsuit, law firms submit thousands of adverse-event reports on behalf of clients, inflating specific signal reactions (e.g., the PPI kidney injury signal).

We analyzed the reporter mix for the benzodiazepine cohort to evaluate this bias:

• The Reporter Profile:
  • Consumers / Patients: 247,076 reports (34.5%).
  • Physicians: 189,477 reports (26.5%).
  • Other Healthcare Professionals: 163,105 reports (22.8%).
  • Pharmacists: 63,592 reports (8.9%).
  • Lawyers: 8,659 reports (1.2%).
• The Litigation Footprint: At only 1.2% of the total cohort, lawyer-submitted reports are low. This confirms that the benzodiazepine FAERS profile is clinically driven. The reports reflect real-world clinical encounters, emergency department visits, and pharmacovigilance reports rather than the influence of mass-tort litigation.

---

FAQ

How many benzodiazepine reports are in FAERS?

There are 716,126 individual reports naming a benzodiazepine in any role in the openFDA FAERS database (export dated June 8, 2026). Of these, 74.5% are classified as serious, and 14.7% record a death outcome.

Which benzodiazepine has the most adverse-event reports?

Alprazolam (Xanax) leads the class with 202,864 reports, followed by clonazepam (153,672), lorazepam (146,479), and diazepam (115,621).

Why is the benzodiazepine death share so high (14.7%)?

The high death share reflects polypharmacy (particularly co-ingestion with opioids), intentional self-harm/suicide, and comorbid patient populations, rather than therapeutic-dose toxicity. Co-ingestion with opioids is a primary driver of respiratory depression.

What is the FDA benzodiazepine boxed warning?

In 2016, the FDA mandated a boxed warning regarding the risks of concomitant use with opioids. On September 23, 2020, the warning was expanded to cover risks of abuse, misuse, addiction, physical dependence, and withdrawal for all benzodiazepines when used alone, mandating individualized gradual tapering.

---

Sources

1. openFDA FAERS Database: Public Adverse Event Reporting System Extract, U.S. Food and Drug Administration, Snapshot June 10, 2026 (data export June 8, 2026). openFDA.
2. FDA Drug Safety Communication: FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class, U.S. Food and Drug Administration, September 23, 2020. FDA.gov.
3. CDC Overdose Mortality Trends: Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines — 38 States and the District of Columbia, 2019–2020, Morbidity and Mortality Weekly Report (MMWR), August 27, 2021. CDC.gov.
4. NIDA Overdose Statistics: Overdose Death Rates, National Institute on Drug Abuse, Updated 2025. NIDA.gov.
5. NIH/PMC Benzodiazepine Mortality Study: Benzodiazepine-Involved Overdose Deaths in the USA 2000-2019: Demographic and Socioeconomic Correlates, Journal of Clinical Psychopharmacology, 2022. PubMed Central PMC9198172.